- Independent data safety monitoring board (DSMB) formally recommends investigational combination therapy advance to Phase 3 following Phase 2 pre-specified analysis for safety and efficacy
- Currently enrolling Phase 3 study enables expansion into a broad range of international trial sites
DURHAM, N.C., United States and BEIJING, China – 29 April 2021 – Brii Biosciences
(“Brii Bio”), a multi-national
company developing innovative therapies for diseases with significant unmet medical needs and large
public health burden, today announced that its monoclonal antibody combination therapy, BRII-196 and
BRII-198, met pre-specified safety and efficacy criteria, permitting continuation of Phase 3 of the
ACTIV-2 trial as recommended by a DSMB composed of independent subject matter experts.
This recommendation is based on an analysis reviewed by the DSMB of approximately 220 patients
enrolled in the Phase 2 portion of the study. Pre-defined safety and efficacy criteria, including
assessments of antiviral activity and clinical efficacy, relative to placebo, were evaluated during
this review in ambulatory patients with COVID-19 at high risk for progression to severe disease.
Brii Biosciences, the study team and the Study Sponsor, the National Institute of Allergy and
Infectious Diseases (NIAID), remain blinded to the data reviewed by the DSMB.
The Phase 3 portion of the study, which has been actively enrolling participants, is expanding into
international trial sites, allowing for a broader assessment of the BRII-196 and BRII-198
combination in ambulatory COVID-19 patients, potentially including data against newly emerged
SARS-CoV2 variants endemic to those countries.
“This recommendation by the independent DSMB is encouraging and marks an important milestone for
Brii Bio as we continue to gather a broad range of data and advance this important investigational
combination therapy for COVID-19 patients around the world,” said Zhi Hong, Ph.D., CEO of Brii Bio.
“As BRII-196 and BRII-198 are the first to progress to Phase 3 evaluation in the ACTIV-2 trial, we
look forward to adding international trial sites to this study, which is especially critical for
regions experiencing a surge in COVID-19 cases and new variants.”
The ACTIV-2 trial (NCT04518410) is
sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), one of the divisions
of the National Institutes of Health (NIH), and is led by the NIAID-funded AIDS Clinical Trials
Group (ACTG). ACTIV-2 is part of NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines
(ACTIV), a public-private partnership program to create a coordinated research strategy that
prioritizes and speeds development of the most promising treatments and vaccines.
The ACTIV-2 master protocol evaluates the safety and efficacy of investigational agents for the
treatment of symptomatic non-hospitalized adults with COVID-19 under a randomized, blinded,
controlled adaptive platform. Participants identified as being at high risk for progression to more
severe disease, are eligible for enrollment onto BRII 196/198 or placebo. Phase 3 evaluation is a
continuation of the Phase 2 trial for agents that meet study-defined criteria for further
evaluation. Phase 3 of the study is designed to determine if the investigational agent, combination
BRII-196 and BRII-198, will prevent the composite endpoint of either hospitalization or death
through study day 28.
About BRII-196 and BRII-198
BRII-196 and BRII-198 are non-competing SARS-CoV-2 neutralizing antibodies derived from convalesced
COVID-19 patients. They have been specifically engineered to reduce the risk of antibody-dependent
enhancement and prolong the plasma half-lives for potentially more durable treatment effect. Their
non-overlapping epitope binding regions provide a high degree of neutralization activity against
SARS-CoV-2, with preliminary in vitro evidence suggesting continued antiviral activity
against commonly circulating variants from U.K. and South Africa. Phase 1 studies in healthy human
volunteers in China have completed dosing and follow-up, providing safety and human pharmacokinetic
profiles for both individual antibodies.
The BRII-196 and BRII-198 antibody cocktail is in Phase 3 clinical investigation as part of the
ongoing NIH ACTIV-2 trial (NCT04518410). Investigational New Drug
applications have been submitted for the combination therapy to the U.S. Food and Drug
Administration (FDA), the Department of Health in Hong Kong, and to the China National Medical
Products Administration (NMPA).
About Brii Biosciences
Brii Biosciences (Brii Bio) is a multi-national company committed to serving patients' needs and
improving public health by accelerating the development and delivery of breakthrough medicines
through partnerships, best-in-class research and development, and the disruptive application of
digital and data insight. With operations in the People's Republic of China and the United States,
Brii Bio is poised to serve as a bridge to carry transformative medicines to patients, help create
significant growth for our partners and establish an innovation engine to help improve the public
health and wellbeing of patients around the world. Brii Bio is developing treatments for illnesses
with significant public health burdens, including infectious diseases and CNS diseases. For more
information, visit www.briibio.com.